Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dispensation Of Schedule II-IV Drugs Must Be Reported Within A Week Under New Law

This article was originally published in The Pink Sheet Daily

Executive Summary

The National All Schedules Prescription Electronic Reporting Act authorizes $60 mil. over five years for states to create or augment Rx monitoring programs.

You may also be interested in...

Rx Controlled Substances Bills Head To President’s Desk

The bills would ease restrictions on exporting controlled substances and limitations on medical practices that treat drug-addicted patients.

Rx Abuse Monitoring Bill Awaits House, Senate Floor Votes

The House and Senate could vote on the "National All Schedules Prescription Electronic Reporting Act" following an agreement by committees to send an identical version to their respective floors. Under HR 1132, states would receive grants to create or augment monitoring systems to track prescriptions of Schedule II-IV drugs across state lines.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts